Cardiotoxicity of 5-fluorouracil: Report of 6 cases;Cardiotoxicité du 5-fluorouracil: À propos de 6 nouveaux cas

Therapie

Volumn 57, Issue 3, 2002, Pages 302-306

  Timour, Q ^a   Lombard Bohas, C ^a   Slim, R ^b   Barel, C ^b   Bui Xuan, B ^a   Tabib, A ^c   Bricca, G ^c   Malonne, H ^a   Vial, T ^b   Iordescu, D ^a   Descotes, J ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

5 fluorouracil; Adverse drug reactions; Cardiotoxicity

Indexed keywords

ATENOLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FUROSEMIDE; GLIBENCLAMIDE; LISINOPRIL; METFORMIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIGESTIVE SYSTEM CANCER; DRUG INDICATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOTHERAPY; SUDDEN DEATH;

EID: 0036588281     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000; 22: 263-302
2. Steinherz LJ. Anthracycline-induced cardiotoxicity. Ann Intern Med 1997; 126: 827-828
3. Kruit WH, Punt KJ, Goey SH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 1994; 74: 2850-2856
4. Brestescher C, Pautier P, Farge D. Chemotherapy and cardiotoxicity. Ann Cardiol Angéiol 1995; 44: 443-447
5. Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol 1998; 10: 377-8
6. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71: 493-509
7. Labianca R, Beretta G, Glenici M, et al. Cardiac toxicity of 5-fluorouracil. Study of 1083 patients. Tumori 1982; 68: 505-510
8. Mizuno Y, Hokamura Y, Kimura T, et al. A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jap Circ J 1995; 59: 303-307
9. Akhtar SS, Wani BA, Bano ZA, et al. 5-fluorouracil-induced severe but reversible cardiogenic shock: a case report. Tumori 1996; 82: 505-507
10. Grandi AM, Pinotti G, Morandi E, et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 1997; 8: 705-708
11. Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol 1998; 10: 377-378
12. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-6
13. Al Attar AF, Skeel RT, Howard JM. Pseudomyxoma peritonei: sudden cardiac death complicating post-operative intraperitoneal treatment with 5-fluorouracil. Digest Surg 1999; 16: 80-82
14. Bégaud B, Evreux JC, Jouglard J, et al. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985; 40: 111-118
15. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33: 1060-1070
16. Becker K, Erckenbrecht JF, Häussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475-484
17. Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729-736
18. Burger AJ, Mannino S. 5-fluorouracil-induced vasospasm. Am Heart J 1987; 114: 433-436
19. Lieutaud T, Brain E, Golgran-Toledano D, et al. 5-fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure ? Eur J Cancer 1996; 32: 368-369
20. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374-378
21. Weidmann B, Jansen W, Heider A, et al. 5-fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 1995; 75: 194-195
22. Porta C, Moroni M, Ferrari S, et al. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 1998; 45: 81-82
23. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995; 9: 561-576
24. Cwikiel M, Eskilsson J, Albertsson M, et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996; 7: 731-737
25. Durak I, Karaayvaz M, Kavutcu M, et al. Reduced antioxydant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health 2000; 59: 585-589
26. Timour Q, Aupetit JF, Freysz M, et al. Possible prevention by amlodipine of ventricular fibrillation related to brief ischemia episodes. Can J Physiol Pharmacol 1996; 43: 50-55
27. Timour Q, Bui-Xuan B, Faucon G, et al. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drug Ther 1996; 10: 447-454
28. Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and litterature report. Am J Clin Oncol 1999; 22: 466-470
29. Maurer U, Harle M, Jungius KP. 5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy? Strahlenther Onkol 1996; 172: 257-259
30. Blutters-Sawatzki R, Grathwohl J, Mertens R, et al. Severe cardiotoxicity of high-dose 5-fluorouracil in combination with folinic acid, cisplatin and methotrexate in a 14-year-old boy with nasopharyngeal carcinoma. Oncology 1995; 52: 291-294
31. Erselcan T, Kairemo KJ, Wiklund TA, et al. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer 2000; 82: 777-781
32. Kohne CH, Thuss-Patience P. Friedrich M. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77: 973-977